BLUE News and Press, bluebird bio Inc. From 02/17/21

AVRO dropped after bluebird's lentiglobin trials were halted because of AML/MDS concerns. Both therapies use Lentiviral vectors, hence the concern. However, Kymriah also uses Lentiviral vectors, and there have been no reports of secondary malignancies. For further details se...

Bluebird bio (BLUE) is paring yesterday’s losses with a ~2.0% gain in the premarket today on below-average volume.However, JP Morgan becomes the latest to downgrade the stock after a string of sell-side resets witnessed yesterday following the company’s announceme...

There's news today that bluebird bio has suspended its gene therapy work on sickle cell disease because of two cases of cancer in its treatment population. Survival rates for bone marrow transplants in general have steadily improved over the years, and everyone knows that one of the r...

bluebird bio ([[BLUE]] -35.3%) keeps plunging as analyst downgrades pile up after the company’s pre-market announcement of the temporary suspension of two clinical trials for its gene therapy candidate, LentiGlobin (“LG”) in sickle cell disease.In the Phase 1/2 (HGB-...

On Tuesday morning, gene therapy specialist bluebird bio (NASDAQ: BLUE) announced the temporary suspension of two of its clinical trials for LentiGlobin, an experimental gene therapy for sickle cell disease (SCD). Shares of the biotech company are falling off a cliff as a result and...

Gainers: Luokung Technology (LKCO) +112%.Kubient (KBNT) +63%.SOS (SOS) +58%.Torchlight Energy Resources (TRCH) +54%.Protective Insurance (PTVCB) +53%.500.com (WBAI) +45%.ALJ Regional (ALJJ) +45%.Urban Tea (MYT) +44%.Canaan (CAN) +36%.Applied Genetic Technologies (AGTC) +32...

Before the open, bluebird bio ([[BLUE]] -33.6%) announced it was suspending two Phase 1/2 clinical trials for the gene therapy candidate, LentiGlobin in sickle cell disease (“SCD”)The investigations were ongoing to determine if there was a relationship to the use of BB305 lentiv...

Gainers: Diffusion Pharmaceuticals (DFFN) +36%, Strongbridge Biopharma (SBBP) +25%, KemPharm (KMPH) +20%, Senseonics Holdings (SENS) +17%, ReWalk Robotics (RWLK) +14%.Losers: bluebird bio (BLUE) -32%, Cortexyme (CRTX) -30%, Inhi...

bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21%&...

bluebird bio (BLUE) has lost ~25.8% in premarket after the company announced the temporary suspension of two clinical trials for its gene therapy candidate, LentiGlobin, and the marketing of ZYNTEGLO™ gene therapy, approved in Europe for transfusion-dependent ;...